Channel and Specialty Data Solutions Business Insights Podcast Series

IQVIA’s Channel and Specialty team’s latest podcast series discuss solutions that leverage real-time data and analytics for end-to-end channel and pipeline visibility. Learn how you can have a deeper understanding of your product from manufacturer to the retail outlet to the patient. Listen in and come back often!

The Changing Specialty Aggregation Ecosystem Pt. 2

IQVIA’s Hari Rayapudi and a group of guest speakers are back for part two. They will be sharing their perspectives around the challenges and interpreting specialty and rare disease data to ensure that there is alignment on insights. We will discuss technical challenges, systems platforms, and standards.

Featured speakers:

  • Hari Rayapudi, Senior Principal, Specialty Data Strategy and Consulting Services, IQVIA
  • Jourdan Masullo, Sr. Director, Patient Services, Kyowa Kirin
  • Natasha Mayfield, General Manager, Optum Frontier Therapies
  • Jessica Mourani, Director, Clinical Outcomes, Trellis Rx
  • Umang Thaker, Director, PSS Oncology Strategy & Management, Novartis

The Changing Specialty Aggregation Ecosystem Pt. 1

In this episode, we will discuss how the specialty and rare disease ecosystems are evolving with new modes of care delivery, patient-centric programming, and expanding data sources.

In part one, we will talk specifically about barriers to patient access and brand strategies to overcome these challenges and share a well-rounded view of the current specialty and rare disease environments. Joining IQVIA’s Hari Rayapudi is an incredibly talented group of industry leaders in specialty patient care for broad, specialty, and rare disease brands.

Featured speakers:

  • Hari Rayapudi, Senior Principal, Specialty Data Strategy and Consulting Services, IQVIA
  • Jourdan Masullo, Sr. Director, Patient Services, Kyowa Kirin
  • Natasha Mayfield, General Manager, Optum Frontier Therapies
  • Jessica Mourani, Director, Clinical Outcomes, Trellis Rx
  • Umang Thaker, Director, PSS Oncology Strategy & Management, Novartis

Staying Compliant in an Evolving World – A SOM Update Pt. 2

In this episode, IQVIA subject matter experts from the Channel and Specialty Data Solutions and Compliance teams will address a group of frequently asked questions around the topic of Suspicious Order Monitoring (SOM) and share some of their insights and real experiences. If you missed episode one, tune in to hear the team talk about Title 21 CFR 1301, the importance of size, patterns and frequencies, and how to use the appropriate and proper data. Plus, the tools that exist to help you stay compliant.  

Featured speakers:

  • Heather Kinney, Director, Offerings Management, IQVIA
  • Paul Hamby, Senior Director, U.S. Regulatory Compliance Solutions, IQVIA
  • Kim Randolph, Associate Director, Product Management, IQVIA
  • Eric Brantley, SOM Engagement Manager, IQVIA


Staying Compliant in an Evolving World – A SOM Update Pt. 1

In this episode, IQVIA Channel and Specialty subject matter experts with members of IQVIA’s Compliance team discuss Suspicious Order Monitoring (SOM). Their conversation focuses on how, in recent years, laws have expanded, adding new legal requirements necessitating existing processes to adapt for manufacturers and distributors to remain compliant while distributing controlled substances. Listen in to gain a better understanding of the updated legislation, new requirements, and supportive data and existing tools that can help you stay compliant.  

Featured speakers:

  • Heather Kinney, Director, Offerings Management, IQVIA
  • Paul Hamby, Senior Director, U.S. Regulatory Compliance Solutions, IQVIA
  • Kim Randolph, Associate Director, Product Management, IQVIA
  • Eric Brantley, SOM Engagement Manager, IQVIA
Contact Us